Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Helenius, M. A.
Right arrow Articles by Visakorpi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Helenius, M. A.
Right arrow Articles by Visakorpi, T.
[Cancer Research 61, 5340-5344, July 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Amplification of Urokinase Gene in Prostate Cancer1

Merja A. Helenius, Outi R. Saramäki, Marika J. Linja, Teuvo L. J. Tammela and Tapio Visakorpi2

Laboratory of Cancer Genetics, Institute of Medical Technology [M. A. H., O. R. S., M. J. L., T. V.], Department of Urology [T. L. J. T.], University of Tampere and Tampere University Hospital, FIN-33014 University of Tampere, Tampere, Finland

Prostate cancer is the most common male malignancy in the United States as well as in many European countries. It is curable as long as it is localized, but the invasion of prostate cancer and formation of metastasis turn it into a life-threatening disease. Urokinase-type plasminogen activator (uPA) is believed to play a key role in tissue degradation and cell migration under various normal and pathological conditions, including cancer invasion and metastasis. Increased expression of uPA has been reported in various malignancies including prostate cancer. However, the mechanisms of the overexpression have remained poorly understood. Here, we report increased copy number of uPA gene in 3 of 13 hormone-refractory prostate carcinomas, including 1 high-level amplification. Real-time quantitative reverse transcription-PCR showed that the increased expression of uPA coincided with the amplification of the gene in these tumors. Matrigel invasion assay showed that prostate cancer cell line PC-3, containing amplification of the uPA gene, was more sensitive to the urokinase inhibitor, amiloride, than DU145 or LNCaP cell lines, which do not have the amplification. The findings suggest that one of the mechanisms underlying the overexpression of the uPA is the amplification of the gene, which is associated with the increased invasive potential of the cells.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
M. K.Y. Siu, E. S.Y. Wong, H. Y. Chan, H. Y.S. Ngan, K. Y.K. Chan, and A. N.Y. Cheung
Overexpression of NANOG in Gestational Trophoblastic Diseases: Effect on Apoptosis, Cell Invasion, and Clinical Outcome
Am. J. Pathol., October 1, 2008; 173(4): 1165 - 1172.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Ferrai, D. Munari, P. Luraghi, L. Pecciarini, M. G. Cangi, C. Doglioni, F. Blasi, and M. P. Crippa
A Transcription-dependent Micrococcal Nuclease-resistant Fragment of the Urokinase-type Plasminogen Activator Promoter Interacts with the Enhancer
J. Biol. Chem., April 27, 2007; 282(17): 12537 - 12546.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Moran, W. Li, B. Fan, R. Vij, C. Eigenbrot, and D. Kirchhofer
Pro-urokinase-type Plasminogen Activator Is a Substrate for Hepsin
J. Biol. Chem., October 13, 2006; 281(41): 30439 - 30446.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. P Singh and R. Agarwal
Mechanisms of action of novel agents for prostate cancer chemoprevention.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Thomas, S. Chigurupati, M. Anbalagan, and G. Shah
Calcitonin Increases Tumorigenicity of Prostate Cancer Cells: Evidence for the Role of Protein Kinase A and Urokinase-Type Plasminogen Receptor
Mol. Endocrinol., August 1, 2006; 20(8): 1894 - 1911.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L.-C. Li, P. R. Carroll, and R. Dahiya
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
D. D. Boyd, S.-J. Kim, H. Wang, T. R. Jones, and G. E. Gallick
A Urokinase-Derived Peptide (A6) Increases Survival of Mice Bearing Orthotopically Grown Prostate Cancer and Reduces Lymph Node Metastasis
Am. J. Pathol., February 1, 2003; 162(2): 619 - 626.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. J. Savinainen, O. R. Saramaki, M. J. Linja, O. Bratt, T. L. J. Tammela, J. J. Isola, and T. Visakorpi
Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate Cancer
Am. J. Pathol., January 1, 2002; 160(1): 339 - 345.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.